Amneal Takes A Step Forward On Biosimilars

FDA Accepts Filing For Bevacizumab Rival To Avastin, Partnered With Mabxience

 
• By Dave Wallace

The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.

Wooden blocks 2021, 2022, 2023
Amneal plans to build up its biosimilars business with a launch every year to 2023 • Source: Alamy

More from Biosimilars

More from Products